Glucocorticoids increase skeletal muscle NF-κB inducing kinase (NIK): Links to muscle atrophy

Physiological Reports

Volumn 4, Issue 21, 2016, Pages

  Fry, Christopher S ^a   Nayeem, Syed Z ^b   Dillon, Edgar L ^b   Sarkar, Partha S ^b   Tumurbaatar, Batbayar ^b   Urban, Randall J ^b   Wright, Traver J ^b   Sheffield Moore, Melinda ^b   Tilton, Ronald G ^b   Choudhary, Sanjeev ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Atrogin 1; Catabolism; Methylprednisolone; MuRF1; NF B inducing kinase

Indexed keywords

FBXO32 PROTEIN, HUMAN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MUSCLE PROTEIN; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; TRIM63 PROTEIN, HUMAN; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; MUSCLE ATROPHY; PATHOLOGY; SKELETAL MUSCLE; SKELETAL MUSCLE CELL;

ANIMALS; GLUCOCORTICOIDS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SKP CULLIN F-BOX PROTEIN LIGASES; TRIPARTITE MOTIF PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84995812423     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13014     Document Type: Article

References (48)

1. Aloisi, F., and R. Pujol-Borrell. 2006. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6:205-217.
2. Amiri, K. I., and A. Richmond. 2005. Role of nuclear factorkappa B in melanoma. Cancer Metastasis Rev. 24:301-313.
3. Ash, Z., C. Gaujoux-Viala, L. Gossec, E. M. Hensor, O. FitzGerald, K. Winthrop, et al. 2012. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann. Rheum. Dis. 71:319-326.
4. Aya, K., M. Alhawagri, A. Hagen-Stapleton, H. Kitaura, O. Kanagawa, and D. V. Novack. 2005. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J. Clin. Invest. 115:1848-1854.
5. Bedard, N., S. Jammoul, T. Moore, L. Wykes, P. L. Hallauer, K. E. Hastings, et al. 2015. Inactivation of the ubiquitinspecific protease 19 deubiquitinating enzyme protects against muscle wasting. FASEB J. 29:3889-3898.
6. Birbach, A., S. T. Bailey, S. Ghosh, and J. A. Schmid. 2004. Cytosolic, nuclear and nucleolar localization signals determine subcellular distribution and activity of the NFkappaB inducing kinase NIK. J. Cell Sci. 117:3615-3624.
7. Bitar, M. S., A. K. Ayed, S. M. Abdel-Halim, E. R. Isenovic, and F. Al-Mulla. 2010. Inflammation and apoptosis in aortic tissues of aged type II diabetes: amelioration with alphalipoic acid through phosphatidylinositol 3-kinase/Aktdependent mechanism. Life Sci. 86:844-853.
8. Bonizzi, G., M. Bebien, D. C. Otero, K. E. Johnson-Vroom, Y. Cao, D. Vu, et al. 2004. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J. 23:4202-4210.
9. Bracken, M. B. 2012. Steroids for acute spinal cord injury. Cochrane Database Syst. Rev. 1:CD001046.
10. Burton, J. M., P. W. O’Connor, M. Hohol, and J. Beyene. 2012. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst. Rev. 12:CD006921.
11. Caiozzo, V. J., Y. Z. Wu, M. J. Baker, and R. Crumley. 2004. Effects of denervation on cell cycle control in laryngeal muscle. Arch. Otolaryngol. Head Neck Surg. 130:1056-1068.
12. Carroll, T. B., and J. W. Findling. 2010. The diagnosis of Cushing’s syndrome. Rev. Endocr. Metab. Disord. 11:147-153.
13. Dalakas, M. C. 2015. Inflammatory muscle diseases. N. Engl. J. Med. 373:393-394.
14. De Iudicibus, S., R. Franca, S. Martelossi, A. Ventura, and G. Decorti. 2011. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J. Gastroenterol. 17:1095-1108.
15. Dejardin, E., N. M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, et al. 2002. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17:525-535.
16. Dhawan, P., A. B. Singh, D. L. Ellis, and A. Richmond. 2002. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62:7335-7342.
17. Fry, C. S., J. D. Lee, J. Mula, T. J. Kirby, J. R. Jackson, F. Liu, et al. 2015. Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. Nat. Med. 21:76-80.
18. Geer, E. B., W. Shen, D. Gallagher, M. Punyanitya, H. C. Looker, K. D. Post, et al. 2010. MRI assessment of lean and adipose tissue distribution in female patients with Cushing’s disease. Clin. Endocrinol. (Oxf) 73:469-475.
19. Geer, E. B., J. Islam, and C. Buettner. 2014. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol. Metab. Clin. North Am. 43:75-102.
20. Gustafson, C. J., C. Watkins, E. Hix, and S. R. Feldman. 2013. Combination therapy in psoriasis: an evidence-based review. Am. J. Clin. Dermatol. 14:9-25.
21. Hanaoka, B. Y., C. A. Peterson, C. Horbinski, and L. J. Crofford. 2012. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat. Rev. Rheumatol. 8:448-457.
22. Hernandez-Jimenez, M., M. I. Ayuso, M. I. Perez-Morgado, E. M. Garcia-Recio, A. Alcazar, M. E. Martin, et al. 2012. eIF4F complex disruption causes protein synthesis inhibition during hypoxia in nerve growth factor (NGF)-differentiated PC12 cells. Biochim. Biophys. Acta 1823:430-438.
23. Huscher, D., K. Thiele, E. Gromnica-Ihle, G. Hein, W. Demary, R. Dreher, et al. 2009. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68:1119-1124.
24. Ishido, M., K. Kami, and M. Masuhara. 2004. Localization of MyoD, myogenin and cell cycle regulatory factors in hypertrophying rat skeletal muscles. Acta Physiol. Scand. 180:281-289.
25. Kelly, H. W., A. L. Sternberg, R. Lescher, A. L. Fuhlbrigge, P. Williams, R. S. Zeiger, et al. 2012. Effect of inhaled glucocorticoids in childhood on adult height. N. Engl. J. Med. 367:904-912.
26. Khaleeli, A. A., R. H. Edwards, K. Gohil, G. McPhail, M. J. Rennie, J. Round, et al. 1983. Corticosteroid myopathy: a clinical and pathological study. Clin. Endocrinol. (Oxf) 18:155-166.
27. Kim, D. H., H. K. Kim, S. Park, J. Y. Kim, Y. Zou, K. H. Cho, et al. 2006. Short-term feeding of baicalin inhibits ageassociated NF-kappaB activation. Mech. Ageing Dev. 127:719-725.
28. Lee, D., and A. L. Goldberg. 2013. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. 288:30515-30526.
29. Lin, X., Y. Mu, E. T. Cunningham Jr, K. B. Marcu, R. Geleziunas, and W. C. Greene. 1998. Molecular determinants of NF-kappaB-inducing kinase action. Mol. Cell. Biol. 18:5899-5907.
30. Liu, P., K. Li, R. P. Garofalo, and A. R. Brasier. 2008. Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-I{middle dot}NF-kappa Binducing kinase signaling pathway. J. Biol. Chem. 283:23169-23178.
31. Malinin, N. L., M. P. Boldin, A. V. Kovalenko, and D. Wallach. 1997. MAP3K-related kinase involved in NFkappaB induction by TNF, CD95 and IL-1. Nature 385:540-544.
32. McPherron, A. C., A. M. Lawler, and S. J. Lee. 1997. Regulation of skeletal muscle mass in mice by a new TGFbeta superfamily member. Nature 387:83-90.
33. Mills, G. H., D. Kyroussis, P. Jenkins, C. H. Hamnegard, M. I. Polkey, J. Wass, et al. 1999. Respiratory muscle strength in Cushing’s syndrome. Am. J. Respir. Crit. Care Med. 160:1762-1765.
34. Moghadam-Kia, S., R. Aggarwal, and C. V. Oddis. 2015. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert. Rev. Clin. Immunol. 11:1265-1275.
35. Ochi, A., T. Abe, R. Nakao, Y. Yamamoto, K. Kitahata, M. Takagi, et al. 2015. N-myristoylated ubiquitin ligase Cbl-b inhibitor prevents on glucocorticoid-induced atrophy in mouse skeletal muscle. Arch. Biochem. Biophys. 570:23-31.
36. Overman, R. A., J. Y. Yeh, and C. L. Deal. 2013. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. (Hoboken) 65:294-298.
37. Pincus, T. 2011. The clinical efficacy of 3 mg/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, double-blind, placebo-controlled withdrawal clinical trial. Clin. Exp. Rheumatol. 29:S73-S76.
38. Qian, T., X. Guo, A. D. Levi, S. Vanni, R. T. Shebert, and M. L. Sipski. 2005. High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 43:199-203.
39. van Raalte, D. H., and M. Diamant. 2014. Steroid diabetes: from mechanism to treatment? Neth. J. Med. 72:62-72.
40. Rayet, B., and C. Gelinas. 1999. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947.
41. Schacke, H., W. D. Docke, and K. Asadullah. 2002. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96:23-43.
42. Uno, M., Y. Saitoh, K. Mochida, E. Tsuruyama, T. Kiyono, I. Imoto, et al. 2014. NF-kappaB inducing kinase, a central signaling component of the non-canonical pathway of NFkappaB, contributes to ovarian cancer progression. PLoS ONE 9:e88347.
43. Urban, R. J., E. L. Dillon, S. Choudhary, Y. Zhao, A. M. Horstman, R. G. Tilton, et al. 2014. Translational studies in older men using testosterone to treat sarcopenia. Trans. Am. Clin. Climatol. Assoc. 125:27-42; discussion 42-24.
44. Vallabhapurapu, S., A. Matsuzawa, W. Zhang, P. H. Tseng, J. J. Keats, H. Wang, et al. 2008. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 9:1364-1370.
45. Walters, J. A., D. J. Tan, C. J. White, and R. Wood-Baker. 2014. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD006897.
46. Woronicz, J. D., X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel. 1997. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278:866-869.
47. Xiao, G., E. W. Harhaj, and S. C. Sun. 2001. NF-kappaBinducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7:401-409.
48. Zarnegar, B. J., Y. Wang, D. J. Mahoney, P. W. Dempsey, H. H. Cheung, J. He, et al. 2008. Noncanonical NFkappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9:1371-1378.